Skip to main content

Advertisement

Table 2 Study outcomes in case and control group

From: The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment

Outcomes HIV+TB (Cases: n = 63) HIV+ (Controls: n = 51) P value
Vital status at 48 week -Weight -Hemoglobin 1. 53.2 ± 8.65 ii. (12.9 ± 1.01 55.7 ± 9.12 12.5 ± 1.52 0.32 0.33
Mortality 13 (20.63%) 4 (7.84%) 0.068
Mean increase in CD4 cell count at 24 weeks from Baseline 108.3 112.7 0.83
Mean increase in CD4 cell count at 48 weeks from Baseline 128.2 148.4 0.69
Viral load suppression at 24 Weeks (≤ 400 copies/ml) 35 (55.5%) -- --
Viral load suppression at 48 Weeks (≤ 400 copies/ml) 37 (58.73%) -- --
Immunological failure 6 (9.5%) 2 (3.9%) 0.313
Virological failure 5 (7.93%) -- --
Clinical Progression at 48 weeks 6 (9.5%) 2 (3.9%) 0.313